Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Encouraging Monkeypox Vaccine Maker To Work With Large Pharma To Up Supply

Executive Summary

The US FDA's Peter Marks also says the intradermal dose-sparing plan was motivated by concern over city and state one-dose strategies. 

You may also be interested in...



Califf Urges Congressional Patience On Opioid Actions

Labeling changes for the pain products remain in active discussion, the US FDA commissioner tells the Senate Health, Education, Labor and Pensions Committee during a hearing on the monkeypox outbreak.

Monkeypox Vaccines – Golden Opportunity Or False Dawn?

While Moderna plans preclinical studies and Tonix Pharma’s candidate is to enter trials in H1, Bavarian Nordic is seeking US and Indian manufacturing partners for its approved monkeypox vaccine. Scrip examines if the disease presents an opportunity for vaccine makers, like COVID-19 did or it could go the H1N1 way

US NIH Testing Strategy To Stretch Monkeypox Vaccine Supply Even Further

The National Institutes of Health is gearing up to launch a trial that would test a smaller intradermal dose of Jynneos than was recently given an emergency use authorization, which could double vaccine supplies relative to currently available intradermal dosing. The trial still will leave the efficacy question unanswered. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS146887

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel